JZJingzhou Zhang

Jingzhou Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingzhou Zhang has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proteomic Associations with Fibrosis and Mortality in Interstitial Lung Abnormalities

    by Jonathan A. Rose, Heida Bjarnadottir, Seung Hoan Choi, Valborg Gudmundsdottir, Jingzhou Zhang, Matthew R. Moll, Sharmin Sultana, Laura Fernandez-Wever, Ann-Marcia C. Tukpah, Claire Cutting, et al.

    Background: Interstitial lung abnormalities (ILA) are CT findings that can represent early-stage pulmonary fibrosis. Radiologic features such as definite fibrosis stratify mortality risk; whether blood-based biomarkers can identify high-risk subsets and predict mortality is unknown.Methods: In this longitudinal multicohort study, we used aptamer-based proteomics in four ILA cohorts (COPDGene, AGES-Reykjavik, SPIROMICS, and the Framingham Heart Study) and one idiopathic pulmonary fibrosis (IPF) cohort. Associations were discovered in COPDGene, replicated in meta-analysis of the other ILA cohorts, and separately the IPF cohort. Logistic regression and Cox models identified protein associations with ILA, fibrotic ILA, and mortality; proteins were combined with demographic variables into a multiprotein model to identify fibrosis and predict mortality.Findings: 13,070 participants were included (1198 with ILA, 267 with fibrotic ILA, 100 with IPF). 231 proteins were associated with ILA in COPDGene, of which eight were associated with fibrotic ILA. In the replication cohorts, 200 proteins replicated with ILA, seven with fibrosis, and six with IPF. An eight-protein model improved discrimination of fibrosis (COPDGene area under the curve [AUC]=0·94; replication AUC=0·79; IPF AUC=0·95) and predicted mortality among those with ILA (COPDGene hazard ratio [HR]=2·5, p<0·001; replication HR=1·9, p<0·001), including when stratified by definite radiologic fibrosis.Interpretation: Peripheral blood proteins are associated with ILA, fibrotic ILA, and mortality. An eight-protein model differentiates radiologic fibrosis and predicts mortality, even in those without definite radiologic evidence of fibrosis, supporting the use of blood-based biomarkers to improve risk stratification of these common radiologic findings.Funding: US National Institutes of Health.

  • Body Mass Index-related genetic factors and COPD imaging phenotypes

    by Jingzhou Zhang, Matthew Moll, Catherine L Debban, Brian D Hobbs, Heena Rijhwani, George R Washko, Bartolome R Celli, Edwin K Silverman, Per Bakke, Elizabeth C Oelsner, et al.

    Rationale: While low body mass index (BMI) is associated with emphysema and obesity is associated with airway disease in chronic obstructive pulmonary disease (COPD), the underlying mechanisms are unclear. Objectives: To examine the association between BMI-related genetic variants and emphysema and airway disease imaging phenotypes. Methods: We aggregated genetic variants from population-based genome-wide association studies to generate a polygenic score of BMI (PGSBMI). We examined associations of the PGSBMI with automated quantification and visual interpretation of computed tomographic emphysema and airway wall thickness (AWT) in COPD-enriched and community-based cohorts. We summarized the results using meta-analysis. Measurements and main results: In the meta-analyses combining results of all cohorts (n = 16 349), a standard-deviation increase of the PGSBMI was associated with less emphysema as quantified by log-transformed percent of low attenuation areas ≤950 Hounsfield units (β = −0.062, P < .0001) and 15th percentile value of lung density histogram (β = 2.27, P < .0001), and increased AWT as quantified by the square root of wall area of a 10-mm lumen perimeter airway (β = 0.016, P = .0006) and mean segmental bronchial wall area percent (β = 0.26, P = .0013). For imaging characteristics assessed by visual interpretation, a higher PGSBMI was associated with reduced emphysema in both COPD-enriched cohorts (odds ratio [OR] for a higher severity grade = 0.89, P = .0080) and in the community-based Framingham Heart Study (OR for the presence of emphysema = 0.82, P = .0034), and a higher risk of airway wall thickening in the COPDGene study (OR = 1.17, P = .0023). Conclusions: In individuals with and without COPD, a higher BMI polygenic risk is associated with both quantitative and visual decreased emphysema and increased AWT, suggesting genetic determinants of BMI affect both emphysema and airway wall thickening.


  • Open Access

    Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes in the COPDGene and ECLIPSE cohort studies

    by Matthew Moll, Julian Hecker, John Platig, Jingzhou Zhang, Auyon J. Ghosh, Katherine A. Pratte, Rui-Sheng Wang, Davin Hill, Iain R. Konigsberg, Joe W. Chiles, et al.


  • Genetically Predicted Body Mass Index and Mortality in Chronic Obstructive Pulmonary Disease

    by Jingzhou Zhang, Matthew Moll, Brian D. Hobbs, Per Bakke, Elizabeth A. Regan, Hanfei Xu, Josée Dupuis, Joe W. Chiles, Merry-Lynn N. McDonald, Miguel J. Divo, et al.

    Rationale: Body mass index (BMI) is associated with chronic obstructive pulmonary disease (COPD) mortality, but the underlying mechanisms are unclear. The effect of genetic variants aggregated into a polygenic score may elucidate the causal mechanisms and predict risk. Objectives: To examine the associations of genetically predicted BMI with all-cause and cause-specific mortality in COPD. Methods: We developed a polygenic score (PGS) for BMI (PGSBMI) and tested for associations of the PGSBMI with all-cause, respiratory, and cardiovascular mortality in participants with COPD from the COPDGene (Genetic Epidemiology of COPD), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), and Framingham Heart studies. We calculated the difference between measured BMI and PGS-predicted BMI (BMIdiff) and categorized participants into groups of discordantly low (BMIdiff 80th percentile) BMI. We applied Cox models, examined potential nonlinear associations of the PGSBMI and BMIdiff with mortality, and summarized results with meta-analysis. Measurements and Main Results: We observed significant nonlinear associations of measured BMI and BMIdiff, but not PGSBMI, with all-cause mortality. In meta-analyses, a one–standard deviation increase in the PGSBMI was associated with an increased hazard for cardiovascular mortality (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.12–1.49), but not for respiratory or all-cause mortality. Compared with participants with concordant measured and genetically predicted BMI, those with discordantly low BMI had higher risks for all-cause mortality (HR, 1.57; 95% CI, 1.41–1.74) and respiratory death (HR, 2.01; 95% CI, 1.61–2.51). Conclusions: In people with COPD, a higher genetically predicted BMI is associated with higher cardiovascular mortality but not respiratory mortality. Individuals with a discordantly low BMI have higher all-cause and respiratory mortality rates than those with a concordant BMI.


  • Open Access

    Variation in Triage to Pediatric vs Adult ICUs Among Adolescents and Young Adults With Asthma Exacerbations

    by Burton H. Shen, Aaron C. Dobie, Sara L. Shusterman, Mine Duzgol, Collin Homer-Bouthiette, Lauren E. Kearney, Julia Newman, Brandon Pang, Divya A. Shankar, Jingzhou Zhang, et al.

  • Association between Early Venous Thromboembolism Prophylaxis, Bleeding Risk, and Venous Thromboembolism among Critically Ill Patients with Thrombocytopenia

    by Brandon Pang, Lauren Kearney, Jennifer Maccarone, Jingzhou Zhang, Christopher Kearney, Ruchika Sangani, Divya A. Shankar, Kari R. Gillmeyer, Anica C. Law, Nicholas A. Bosch


  • Genetic Risk for Body Mass and Mortality in COPD

    by J. Zhang, M. Moll, B.D. Hobbs, P. Bakke, E.A. Regan, E.K. Silverman, G.T. O'COnnor, M.H. Cho

  • A polygenic risk score and age of diagnosis of COPD

    by Jingzhou Zhang, Hanfei Xu, Dandi Qiao, Dawn L. DeMeo, Edwin K. Silverman, George T. O'COnnor, Brian D. Hobbs, Josée Dupuis, Michael H. Cho, Matthew Moll

    Background: Genetic susceptibility may be associated with earlier onset of chronic obstructive pulmonary disease (COPD). We hypothesised that a polygenic risk score (PRS) for COPD would be associated with earlier age of diagnosis of COPD. Methods: In 6647 non-Hispanic White (NHW) and 2464 African American (AA) participants from COPDGene, and 6812 participants from the Framingham Heart Study (FHS), we tested the relationship of the PRS and age of COPD diagnosis. Age at diagnosis was determined by: 1) self-reported age at COPD diagnosis or 2) age at visits when moderate-to-severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 2–4) was observed on spirometry. We used Cox regression to examine the overall and time-dependent effects of the PRS on incident COPD. In the COPDGene study, we also examined the PRS's predictive value for COPD at age e.g. childhood asthma). Results: In Cox models, the PRS demonstrated age-dependent associations with incident COPD, with larger effects at younger ages in both cohorts. The PRS was associated with COPD50 (OR 1.55 (95% CI 1.41–1.71) for NHW, OR 1.23 (95% CI 1.05–1.43) for AA and OR 2.47 (95% CI 2.12–2.88) for FHS participants). In COPDGene, adding the PRS to known early-life risk factors improved prediction of COPD50 in NHW (AUC 0.69 versus 0.74; pversus 0.64; p=0.04) participants. Conclusions: A COPD PRS is associated with earlier age of diagnosis of COPD and retains predictive value when added to known early-life risk factors.


  • Comorbidities of Rare Epilepsies: Results from the Rare Epilepsy Network

    by Nhan Thi Ho, Barbara Kroner, Zachary Grinspan, Brandy Fureman, Kathleen Farrell, Jingzhou Zhang, Janice Buelow, Dale C. Hesdorffer, Brianne McDonald, Monica Weldon, et al.


  • Spirometry reference values for population aged 7–80 years in China

    by Jingzhou Zhang, Xiao Hu, Guangliang Shan

    Background and objective: Lung function tests are widely used in clinical and public health practice; however, no valid spirometry reference values were available for the general population in China. This study aimed to provide valid spirometry predictive equations for the general population in China, and to evaluate the predictive performance of previously used equations.Methods: Data from the China National Health Survey 2012–2015 and the ‘Generalized Additive Models for Location, Scale and Shape’ statistical modelling method were used to establish spirometry predictive equations for forced expiratory volume in 1 s (FEV1 ), forced vital capacity (FVC) and FEV1/FVC. Paired t‐tests were used to examine differences between spirometry measurements in this sample and predicted values of four previous spirometry predictive equations.Results: This study included 3130 lifetime non‐smokers (713 males and 2417 females) aged 7–80 years in China. Spirometry predictive equations with age and height as predictive variables plus age‐specific splines were established separately by gender. Most previous spirometry predictive equations were found to significantly overestimate (maximum of 3.69% in FEV1, 1.87% in FVC and 4.19% in FEV1/FVC for males; 11.46% in FEV1, 7.28% in FVC and 3.78% in FEV1/FVC for females) or underestimate (maximum of 5.75% in FEV1 and 8.12% in FVC for males; 7.89% in FEV1 and 9.32% in FVC for females) lung function measurements when applied to this sample population.Conclusion: This study addressed the urgent need for valid and up‐to‐date spirometry reference values for the general population in China. Moreover, previous spirometry predictive equations showed unfavourable generalizability to this sample population.